Screener
Nuvation Bio NUVB US — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| Line item | For the three months ended June 30, 2026 | For the three months ended June 30, 2025 | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|---|---|
| United States | $23,192 | $1,238 | $100,579 | $1,238 |
| China | 7,991 | 3,354 | 13,180 | 6,254 |
| Japan | 504 | 241 | 1,156 | 425 |
| Total revenue | $31,687 | $4,833 | $114,915 | $7,917 |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's US — revenue?
- Nuvation Bio (NUVB) reported US — revenue of $23.19M in Q2 2026.
- How has Nuvation Bio's US — revenue changed year-over-year?
- Nuvation Bio's US — revenue increased by 1773.3% year-over-year, from $1.24M to $23.19M.
- What does US — revenue mean?
- Represents the total gross income generated from the sale of goods or services within the United States geographic segment. This metric serves as a primary indicator of market penetration and commercial success for the company's therapeutic offerings in the domestic market. It reflects the aggregate value of all recognized revenue streams attributed to US-based operations.
Ask your AI about Nuvation Bio's us — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude